Fisher Asset Management LLC Acquires 23,991,451 Shares of AbbVie Inc. $ABBV

Fisher Asset Management LLC boosted its holdings in AbbVie Inc. (NYSE:ABBV) by 252.6% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 33,489,421 shares of the company’s stock after acquiring an additional 23,991,451 shares during the period. AbbVie accounts for 2.5% of Fisher Asset Management LLC’s holdings, making the stock its 8th biggest position. Fisher Asset Management LLC owned about 1.89% of AbbVie worth $8,760,498,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of ABBV. State Street Corp lifted its holdings in shares of AbbVie by 1.7% during the second quarter. State Street Corp now owns 82,596,748 shares of the company’s stock worth $20,784,646,000 after buying an additional 1,379,232 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in AbbVie by 0.7% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,267,697 shares of the company’s stock valued at $3,590,323,000 after acquiring an additional 106,091 shares during the last quarter. Legal & General Group Plc bought a new stake in shares of AbbVie during the 2nd quarter worth $2,905,952,000. Deutsche Bank AG boosted its stake in shares of AbbVie by 13.0% in the 2nd quarter. Deutsche Bank AG now owns 10,772,949 shares of the company’s stock valued at $2,710,905,000 after purchasing an additional 1,241,587 shares in the last quarter. Finally, Amundi boosted its position in AbbVie by 2.4% in the first quarter. Amundi now owns 10,698,095 shares of the company’s stock valued at $2,326,728,000 after buying an additional 247,689 shares in the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

AbbVie Stock Performance

NYSE ABBV opened at $294.75 on Friday. AbbVie Inc. has a fifty-two week low of $190.75 and a fifty-two week high of $302.93. The stock has a 50 day simple moving average of $274.82 and a two-hundred day simple moving average of $240.55. The stock has a market cap of $521.01 billion, a P/E ratio of 50.73, a price-to-earnings-growth ratio of 1.34 and a beta of 0.20.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Friday, October 30th. The company reported $3.82 EPS for the quarter, topping analysts’ consensus estimates of $3.73 by $0.09. The company had revenue of $17.40 billion during the quarter, compared to analyst estimates of $17.32 billion. AbbVie had a negative return on equity of 450.55% and a net margin of 15.67%. The firm’s revenue was up 10.3% on a year-over-year basis. During the same quarter last year, the firm posted $1.86 earnings per share. Sell-side analysts predict that AbbVie Inc. will post 13.98 earnings per share for the current year.

AbbVie Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, February 16th. Stockholders of record on Friday, January 15th will be given a $1.82 dividend. The ex-dividend date of this dividend is Friday, January 15th. This represents a $7.28 annualized dividend and a dividend yield of 2.5%. This is a positive change from AbbVie’s previous quarterly dividend of $1.73. AbbVie’s dividend payout ratio is 119.10%.

Insider Activity at AbbVie

In other news, EVP Jeffrey Stewart sold 40,619 shares of AbbVie stock in a transaction dated Monday, November 9th. The shares were sold at an average price of $293.60, for a total transaction of $11,925,738.40. Following the sale, the executive vice president owned 83,171 shares of the company’s stock, valued at approximately $24,419,005.60. The trade was a 32.81% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.06% of the company’s stock.

AbbVie News Summary

Investors following ABBV have been watching these news items:

• Positive Sentiment: AbbVie’s immunology sales rose 16.6% in the third quarter, with Skyrizi and Rinvoq growth more than offsetting Humira’s decline. The performance has supported higher 2026 sales expectations and strengthens the case that newer drugs can sustain growth. How Did AbbVie’s Immunology Franchise Fare in Q3?
• Neutral Sentiment: A Crohn’s disease study update drew coverage describing its likely near-term stock impact as limited; it does not appear to materially change the immediate investment outlook. AbbVie Crohn’s Disease Study Update
• Negative Sentiment: Executive Vice President Jeffrey Stewart sold 40,619 shares for about $11.9 million, reducing his direct holdings by 32.81%. Insider sales can weigh on sentiment, though the filing does not explain the reason for the transaction. SEC Form 4 filing

Analysts Set New Price Targets

A number of analysts recently weighed in on the company. UBS Group increased their price objective on AbbVie from $275.00 to $295.00 and gave the company a “neutral” rating in a report on Monday, November 2nd. BNP Paribas Exane raised their price objective on AbbVie from $218.00 to $247.00 and gave the company a “neutral” rating in a research note on Tuesday, August 11th. Wells Fargo & Company boosted their price target on shares of AbbVie from $300.00 to $340.00 and gave the stock an “overweight” rating in a report on Monday, November 2nd. Sanford C. Bernstein reiterated a “market perform” rating and issued a $275.00 price objective on shares of AbbVie in a research note on Monday, November 2nd. Finally, Argus upped their price target on shares of AbbVie from $250.00 to $270.00 in a report on Tuesday, August 4th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $297.46.

AbbVie Company Profile

AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.